HF
TCRT icon

HRT Financial’s Alaunos Therapeutics TCRT Stock Holding History

HRT Financial’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,327
Closed -$38K – 5314
2026
Q1 		$38K Buy
13,327
+725
+6% +$2.17K ﹤0.01% 3490
2025
Q4 		$40K Buy
+12,602
New +$40.7K ﹤0.01% 2905
2024
Q3 		– Sell
-1,048
Closed -$7K – 3119
2024
Q2 		$7K Buy
+1,048
New +$12.5K ﹤0.01% 2020
2023
Q1 		– Sell
-122
Closed -$11K – 3177
2022
Q4 		$11K Buy
+122
New +$17.7K ﹤0.01% 2218
2022
Q1 		– Sell
-320
Closed -$52K – 3841
2021
Q4 		$52K Sell
320
-3,941
-92% -$866K ﹤0.01% 2840
2021
Q3 		$1.16M Buy
4,261
+2,648
+164% +$810K 0.01% 1132
2021
Q2 		$638K Buy
+1,613
New +$753K 0.01% 1554
2019
Q4 		– Sell
-247
Closed -$158K – 1623
2019
Q3 		$158K Buy
+247
New +$196K 0.01% 1192
2015
Q3 		– Sell
-106
Closed -$190K – 180
2015
Q2 		$190K Buy
+106
New +$165K 0.09% 124

Other funds holding TCRT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

HRT Financial's TCRT Position: Q2 2026 in Review

HRT Financial sold out of Alaunos Therapeutics (TCRT) in Q2 2026, closing a stake of 13,327 shares — an estimated $38K sold.

HRT Financial first reported a position in TCRT in Q2 2015 and held it in 9 quarters. The position peaked at $1.16M in Q3 2021. 29 funds tracked by Wall St. Rank hold TCRT as of Q2 2026.

  • HRT Financial reported no remaining Alaunos Therapeutics position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 13,327 Alaunos Therapeutics shares in Q2 2026, an estimated $38K.
  • HRT Financial first reported a position in Alaunos Therapeutics in Q2 2015 and held it in 9 quarters.
  • HRT Financial's Alaunos Therapeutics position peaked at $1.16M in Q3 2021.
  • 29 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.